CurrentBlue Cross Blue Shield - MassachusettsPolicy 247

Hematopoietic Cell Transplantation for Germ Cell Tumors — Autologous and Allogeneic HCT

This policy governs medical necessity and prior authorization for autologous and allogeneic hematopoietic cell transplantation (HCT) for germ cell tumors for Blue Cross Blue Shield Massachusetts members across commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyHematopoietic Cell Transplantation for Germ Cell Tumors — Autologous and Allogeneic HCT

Policy CodePolicy 247

Change TypeAnnual reviewcoding/authorization clarifications

Effective Date

Next Review Date

Key ActionSubmit initial authorization requests using Authorization Manager with facility and servicing provider NPIs and include clinical documentation that meets medical policy guidelines.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Single autologous HCTmay be considered medically necessary as salvage therapy

Tandem autologous HCTmay be considered medically necessary for testicular tumors

Autologous HCTinvestigational as first-line treatment

Allogeneic HCTconsidered investigational for germ cell tumors

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior authorizationauthorization requirement

Coverage and Medical Necessity Criteria

Medically Necessary Indications

Covered when ANY of the following are met:

Single autologous HCT — salvage after conventional-dose salvage chemotherapy: Single autologous HCT is medically necessary as salvage therapy for germ cell tumors in individuals with favorable prognostic factors who have failed a previous course of conventional-dose salvage chemotherapy.

Favorable prognostic factors include testis or retroperitoneal primary site, complete response to initial chemotherapy, low serum tumor markers, and low-volume disease.

Single autologous HCT — first relapse or platinum-refractory with unfavorable factors: Single autologous HCT is medically necessary as initial treatment of first relapse (ie, without a course of conventional-dose salvage chemotherapy) and for platinum-refractory disease in individuals with unfavorable prognostic factors.

Unfavorable prognostic factors include extratesticular primary site, incomplete response to initial therapy, high serum tumor markers, high-volume disease, or relapsing mediastinal nonseminomatous germ cell tumors.

Tandem or sequential high-dose autologous HCT for testicular tumors: Tandem autologous HCT or transplant with sequential high-dose chemotherapy may be considered medically necessary for the treatment of testicular tumors as salvage therapy or for platinum-refractory disease.

Not recommended as first-line

Autologous HCT not supported as first-line: Autologous HCT is considered investigational as a component of first-line treatment for germ-cell tumors and is not supported as routine initial therapy.

Randomized trials did not demonstrate improved outcomes with autologous HCT as initial therapy.

Investigational Indications

Allogeneic HCT investigational: Allogeneic HCT is considered investigational to treat germ cell tumors, including use after prior failed autologous HCT.

Evidence limited to case reports; no comparative trials.

Coverage conclusions

Summary conclusions of evidence-based coverage considerations

Autologous HCT as first-line therapy: Randomized trials have not shown significant improvement in outcomes (OS, DSS) with autologous HCT as initial therapy compared with standard-dose chemotherapy; the evidence is insufficient to determine a net health benefit.

RCTs were relatively small and may have been underpowered.

Autologous HCT for relapsed/refractory disease: Evidence for autologous HCT in relapsed/refractory disease includes one RCT and several case series; the RCT did not demonstrate improved outcomes with high-dose chemotherapy and autologous HCT versus standard-dose chemotherapy, while series report variable PFS and OS with some 2–3 year PFS of 50–60%; overall evidence is insufficient to confirm net benefit.

Outcomes vary by prior therapy, prognostic factors, and number of HDC cycles.

Tandem/sequential HDC with autologous transplant: An RCT reported higher treatment-related mortality with sequential high-dose chemotherapy compared with single high-dose chemotherapy, with no significant difference in 5‑year survival; heterogeneous study populations and lack of consistent prognostic scoring limit conclusions; insufficient evidence of benefit.

Autologous hematopoietic cell transplantation (HCT) as first‑line therapy for germ‑cell tumors is considered investigational and is not supported as a covered indication. The policy states that autologous HCT is investigational when used as a component of initial (first‑line) treatment because randomized trials have not demonstrated significant improvements in overall or disease‑specific survival compared with standard‑dose chemotherapy, and the evidence is insufficient to show a net health benefit.

Available data do not demonstrate a clear benefit from tandem (sequential) autologous transplantation or sequential high‑dose chemotherapy in germ‑cell tumors. A randomized trial reported higher treatment‑related mortality with sequential high‑dose chemotherapy compared with single high‑dose chemotherapy and no significant difference in 5‑year survival, and cohort studies are heterogeneous. Consequently, tandem/sequential strategies have not shown consistent benefit, including in patients with primary mediastinal germ‑cell tumors.

The evidence is insufficient to conclude that autologous HCT as initial (first‑line) therapy improves clinically meaningful outcomes for previously untreated germ‑cell tumors. Randomized controlled trials have not shown significant improvement in overall survival or disease‑specific survival versus alternative therapies, and small sample sizes and potential underpowering limit confidence in those results.

Overall, the body of evidence does not support routine use of initial or tandem high‑dose strategies with autologous HCT for germ‑cell tumors. Trials and series are heterogeneous with variable outcomes, and an RCT identified increased treatment‑related mortality with sequential high‑dose regimens without clear survival advantage; therefore, high‑dose/tandem strategies and autologous HCT as first‑line therapy lack sufficient evidence of net health benefit.

First-line and Salvage Therapy Considerations

first-line

First-line autologous HCT: Autologous HCT as first-line therapy is considered investigational and not supported by evidence of improved overall survival or progression-free survival compared with standard-dose chemotherapy.

Randomized trials did not demonstrate benefit; evidence insufficient.

salvage

Salvage autologous HCT: Autologous HCT may be medically necessary as salvage therapy for relapsed or refractory germ cell tumors when applied according to prognostic groupings and prior therapy status.

Evidence includes an RCT and case series with variable outcomes; some series report 2–3 year PFS of 50–60% in selected patients.

first-line (additional evidence context)

Regimens and Transplant Types

Regimen	Evidence summary	Outcomes / notes	Coverage stance
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation (single HDC with autologous HCT)
Evidence includes one randomized controlled trial (RCT) and several case series evaluating HDC with autologous HCT in relapsed/refractory germ cell tumors.
Case series report variable progression-free survival (PFS) and overall survival (OS); 2–3 year PFS of ~50–60% reported in series. RCT did not show improved outcomes versus standard-dose chemotherapy in relapsed/refractory settings.
may be considered medically necessary in selected salvage settings per prognostic factors

Regimen	Evidence summary	Outcomes / notes	Coverage stance
Tandem/sequential high-dose chemotherapy with autologous hematopoietic stem-cell transplantation (sequential HDC/tandem autologous HCT)
Evidence includes an RCT, retrospective cohort studies, and comparative reviews; patient populations heterogeneous and studies lack consistent prognostic stratification.
RCT reported higher treatment-related mortality (TRM) with sequential HDC compared with single HDC; 5-year survival not significantly different. Tandem/sequential approaches have not demonstrated consistent net benefit, and no benefit shown in primary mediastinal germ cell tumors.
insufficient evidence / may be considered on a case-by-case salvage basis but associated with higher TRM

Procedure and Billing Codes

Covered CPT CodesCPTCovered

38241

Hematopoietic progenitor cell (HPC); autologous transplantation

Covered HCPCS CodesHCPCSCovered

S2150

Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)

Investigational CPT CodesCPTExperimental

38240

Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor

Investigational HCPCS CodesHCPCSExperimental

S2142

Cord blood derived stem-cell transplantation, allogeneic

Coding notesmixed

No codes listed

Authorization, Documentation, and Submission Instructions

Billing Rule

Coverage contingent on meeting medical necessity

Prior authorization is required for services described in this policy when performed inpatient or outpatient as specified below. Coverage for the procedure codes listed in the policy is contingent upon meeting the written medical necessity criteria in this policy; inclusion of a code in the policy does not by itself guarantee coverage or reimbursement — verify the member's contract benefits at the time of service.

Covered codes are covered only when the policy's medical necessity criteria are met.
Inclusion of a code in the policy is informational and does not imply coverage — check member benefits.

Prior Authorization

Prior authorization required — Inpatient

Precertification/preauthorization IS REQUIRED for inpatient services described in this policy.

Laboratory and Biomarker Requirements

AFP, hCG, LDH — required tumor markers and related requirements

Required tumor markersAFP (alpha-fetoprotein), hCG (human beta-chorionic gonadotropin), LDH (lactate dehydrogenase)

PurposeUsed for staging and prognostic categorization of germ cell tumors

Marker behaviorMost patients with pure seminoma have normal AFP; marker elevations used to assign S0–S3 burden categories

Integration with stagingTNM staging is modified by serum marker concentrations (S0–S3) when available

Key Definitions

Autologous HCT — definition and brief explanation

DefinitionAutologous HCT: hematopoietic stem cells are harvested from the patient and reinfused after high‑dose, marrow‑ablative therapy; immunologic compatibility between infused cells and recipient is not an issue.

Cell sourcesStem cells may be harvested from bone marrow, peripheral blood, or umbilical cord blood (when autologous source available)

Typical roleUsed to restore bone marrow and immune function after bone marrow‑toxic cytotoxic drugs with or without whole‑body radiotherapy

Clinical contextConsidered primarily as consolidation or salvage therapy depending on disease response and prognostic factors

Allogeneic HCT — definition and brief explanation

DefinitionAllogeneic HCT: hematopoietic stem cells obtained from a donor and infused into the patient; requires HLA typing and management of graft‑versus‑host disease with post‑transplant immunosuppression.

Clinical Background

Germ‑cell tumors comprise primarily testicular neoplasms but also include ovarian and extragonadal tumors (for example, mediastinal and central nervous system germ‑cell tumors). Classification and treatment decisions are guided by histology, stage (including TNM and marker‑modified staging), and serum tumor markers such as AFP, hCG, and LDH. Prognostic categorization (favorable versus unfavorable) informs consideration of HCT: favorable prognostic factors include a testis or retroperitoneal primary site, complete response to initial chemotherapy, low serum markers, and low‑volume disease; unfavorable prognostic factors include extratesticular primary site, incomplete response to initial therapy, high serum markers, high‑volume disease, or relapsing mediastinal nonseminomatous germ‑cell tumors.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyHematopoietic Cell Transplantation for Germ Cell Tumors — Autologous and Allogeneic HCT

Policy CodePolicy 247

Change TypeAnnual reviewcoding/authorization clarifications

Effective Date

Next Review Date

Key ActionSubmit initial authorization requests using Authorization Manager with facility and servicing provider NPIs and include clinical documentation that meets medical policy guidelines.

SourceLink

On This Page

Tandem/sequential HDC has not shown benefit in primary mediastinal germ cell tumors.

Allogeneic HCT: Evidence for allogeneic HCT is limited to case report(s); there are no RCTs or comparative studies and the evidence is insufficient to determine improvement in net health outcome.

One 2007 case report described successful treatment of a refractory mediastinal germ cell tumor.

First-line (additional evidence context): Randomized trials do not show benefit for autologous HCT as first-line therapy compared with standard-dose chemotherapy; the evidence is insufficient to support routine use.

Study sample sizes were relatively small and may have been underpowered.

salvage (additional evidence context)

Salvage (additional evidence context): For relapsed or refractory disease, evidence comprises a single RCT and multiple series; the RCT did not find improved outcomes with HDC/autologous HCT versus standard-dose chemotherapy, and series report variable durable PFS in subsets; overall evidence is insufficient to confirm net health benefit.

Heterogeneity in prior treatments, prognostic factors, and number of HDC/transplant cycles affects outcomes.

Inpatient: precertification/preauthorization required for all products.

Prior Authorization

Prior authorization required — Outpatient

Prior authorization IS REQUIRED for outpatient services for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members.

Outpatient: Prior authorization required for Commercial Managed Care (HMO and POS).
Outpatient: Prior authorization required for Commercial PPO and Indemnity.
Outpatient: Prior authorization required for Medicare HMO Blue SM and Medicare PPO Blue SM.
Policy history documents changes to outpatient prior authorization requirements — check current rules as these have changed over time.

Prior Authorization

How to submit authorization

Providers must submit authorization requests using Authorization Manager (available 24/7). Include the facility NPI/provider ID where services will be performed and the servicing provider's NPI/provider ID (surgeon/ordering clinician), not just the billing group. For commercial members, requests must demonstrate that the service meets the medical policy guidelines.

Use Authorization Manager to submit initial authorization requests and clinical documentation.
Enter facility NPI/provider ID and the servicing provider's NPI/provider ID.
Attach clinical documentation supporting how the member meets the policy's medical necessity criteria.

Documentation Required

Documentation and coding

Documentation must clearly support the clinical indications required by this policy. Medical records should include tumor histology, disease stage, primary tumor site, prior chemotherapy regimens and response (including whether relapse is platinum-refractory), serum tumor marker levels, and characterization of disease volume. Coding should follow current industry-standard CPT/HCPCS/ICD-10 codes and modifiers; the policy's coding clarifications in the policy history should be followed.

Document tumor histology, stage, primary site, prior chemotherapy and response, serum marker levels, and disease volume.
Report services with current CPT/HCPCS/ICD-10 codes and appropriate modifiers.
Refer to policy history for recent coding clarifications and updates.

Note

Clinical decision context and salvage vs first-line

Clinical decision-making for use of hematopoietic cell transplantation (HCT) in germ cell tumors depends on multiple factors: disease stage, tumor histology, primary site, response to prior chemotherapy, and prognostic factors (favorable vs unfavorable). The policy specifies that single autologous HCT and tandem autologous HCT are considered medically necessary as salvage therapy or for platinum-refractory disease, while autologous HCT as a component of first-line treatment and allogeneic HCT are investigational. This policy therefore defines salvage versus first-line indications rather than imposing a step-therapy sequence.

Consider HCT for patients with unfavorable prognostic factors or those who have failed conventional-dose salvage chemotherapy (favorable prognostic factors) or as initial treatment of first relapse for unfavorable prognostic factors.
Autologous HCT is investigational as first-line therapy; allogeneic HCT is investigational for germ cell tumors.
This policy specifies salvage vs first-line indications rather than step-therapy sequencing; do not interpret it as a required step-therapy algorithm.

Compatibility requirementDonor–recipient immunologic compatibility is established by HLA typing (A, B, DR loci); acceptable donors match at all or most loci

Cell sourcesDonor cells can be obtained from bone marrow, peripheral blood, or umbilical cord blood

Evidence/stanceAllogeneic HCT is considered investigational for germ cell tumors per policy (limited evidence).

Unfavorable prognostic factors — factors influencing HCT candidacy

Unfavorable prognostic factors — overviewCharacteristics that increase risk and may make patients candidates for HCT assessment (influence salvage vs first‑line decisions)

Primary siteExtratesticular (eg, mediastinal) primary site — associated with poorer prognosis

Response to initial therapyIncomplete response to initial chemotherapy or platinum‑refractory disease

Serum tumor markersHigh serum marker levels (eg, elevated AFP, hCG, LDH consistent with S2–S3) — associated with unfavorable prognosis

Disease burdenHigh‑volume disease or presence of nonpulmonary visceral metastases — adverse prognostic feature